The drug company Zeneca Group, manufacturer of the breast cancer drugs Arimidex and Tamoxifen, founded National Breast Cancer Awareness Month in 1985 in order to promote x-ray mammography -- and their own products. But recent research shows that x-ray mammography screening may help only 1 person per 2,500 screened, while at least 1,000 of those 2,500 will have a false alarm, 500 will undergo an unnecessary biopsy, and 5 or more will receive even more extreme unnecessary treatment. Meanwhile, a growing body of evidence indicates that the x-rays used in breast screenings are up to 500% more carcinogenic than previously assumed.
It is important to note that the Zeneca Group (which is now known as AstraZeneca) is a subsidiary of Imperial Chemical Industries (ICI), which has produced millions of pounds of known mammary carcinogens such as vinyl chloride. AstraZeneca's best-selling cancer drug Tamoxifen is actually itself classified by the World Health Organization as a carcinogen. A number of experts and organizations are concerned by this glaring conflict of interest.
According to Green Med Info:
“When it comes to the breast cancer industry’s emphasis on equating ‘prevention’ with ‘early detection’ through x-ray mammography, nowhere is the inherently pathological ideology of allopathic medicine more clearly evident. Not only is the very ionizing radiation used to discern pathological lesions in breast tissue one of the very risk factors for the development of breast cancer, but the identification of the word ‘prevention’ with ‘early detection,’ is a disingenuous way of saying that all we can do to prevent breast cancer is to detect its inevitable presence sooner than would be possible without this technology ... Fortunately there are thousands of scientific studies extant today on the therapeutic value of foods, herbs and spices in breast health”.